Form 4: Werewolf Therapeutics Director Acquires Stock Options

Anil K. Singhal, a director of Werewolf Therapeutics, Inc., was granted stock options to purchase 45,000 shares of common stock on February 19, 2025.

Summary

• Anil K. Singhal, a director at Werewolf Therapeutics, Inc. (HOWL), was granted stock options on February 19, 2025.
• The options allow Singhal to purchase 45,000 shares of Werewolf Therapeutics' common stock at an exercise price of $1.40 per share.
• The options vest over three years, with one-third vesting on February 19, 2026, and the remaining shares vesting in equal monthly installments thereafter.
• The options expire on February 18, 2035.
• Following the transaction, Singhal directly owns 45,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants. It's neutral in tone and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Future Outlook

The vesting schedule of the options suggests a long-term commitment from the director to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.

Key Dates

Keywords

stock options, director, Werewolf Therapeutics, HOWL, Form 4, beneficial ownership, insider trading